FDA
-
-
-
-
-
-
-
Biogen's Empaveli cuts proteinuria 75% in teens with rare kidney disease
-
-
-
-
-
-
-
Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S.
-
-
-
-
-
-
-
Real-world Leqembi study shows 82% of Alzheimer's patients stable
-
-
-
-
-
-
-
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
-
-
-
-
-
-
-
International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
-
-
-
-
-
-
-
Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s
-
-
-
-
-
-
-
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
-
334,836 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


